13F filer · CIK 1631134
Sofinnova Investments, Inc.
Menlo Park, CA · filing since Q1 2018 · last filing Aug 14, 2026
Reported value
$1.9B
$-696.9M vs prior
Positions
57
New / sold out
13 / 30
Added / reduced
14 / 17
Turnover
15.5%
buys $354.0M · sells $1.3B
Top-10 weight
57.9%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | Genmab A/S | +3,292,954 | +437.7% | +$90.5M |
| New | Seaport Therapeutics Inc | +3,564,871 | – | +$77.4M |
| New | Gilead Sciences Inc | +343,100 | – | +$43.3M |
| Added | Anaptysbio Inc | +245,283 | +98.8% | +$16.6M |
| New | Intuitive Surgical IncCALL | +40,000 | – | +$15.9M |
| New | Globus Med IncCALL | +200,000 | – | +$15.8M |
| New | Nurix Therapeutics Inc | +524,098 | – | +$12.7M |
| New | Design Therapeutics Inc | +865,135 | – | +$12.5M |
| New | First Tracks Biotherapeutics | +565,199 | – | +$11.4M |
| New | Abbott Laboratories | +122,998 | – | +$11.2M |
17 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | iShares TRPUT | -600,000 | -100.0% | $-148.8M |
| Sold out | SPDR Series TrustPUT | -1,050,000 | -100.0% | $-134.1M |
| Sold out | AstraZeneca PLC | -456,031 | -100.0% | $-89.9M |
| Sold out | Invesco QQQ TRPUT | -150,000 | -100.0% | $-86.6M |
| Sold out | iShares TRPUT | -475,000 | -100.0% | $-80.2M |
| Reduced | Bristol-Myers Squibb Co | -1,111,751 | -55.9% | $-64.1M |
| Reduced | Jazz Pharmaceuticals PLC | -232,986 | -38.9% | $-56.1M |
| Reduced | Ultragenyx Pharmaceutical In | -1,428,383 | -45.4% | $-47.7M |
| Sold out | United Therapeutics CorpPUT | -80,300 | -100.0% | $-47.6M |
| Reduced | United Therapeutics Corp Del | -83,581 | -52.2% | $-45.3M |
37 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Natera IncCOM | 1,550,280 | $420.8M | 21.76% |
| 2 | Vera Therapeutics IncCL A | 2,793,987 | $119.9M | 6.20% |
| 3 | Genmab A/SSPONSORED ADS | 4,045,215 | $111.1M | 5.74% |
| 4 | Jazz Pharmaceuticals PLCSHS USD | 365,341 | $88.0M | 4.55% |
| 5 | Rapport Therapeutics IncCOM | 1,904,408 | $79.4M | 4.10% |
| 6 | Seaport Therapeutics IncCOM | 3,564,871 | $77.4M | 4.00% |
| 7 | Arrivent BioPharma IncCOM | 1,696,752 | $58.9M | 3.05% |
| 8 | Ultragenyx Pharmaceutical InCOM | 1,717,505 | $57.3M | 2.96% |
| 9 | BioAge Labs IncCOM | 2,293,788 | $56.2M | 2.91% |
| 10 | Bristol-Myers Squibb CoCOM | 876,970 | $50.5M | 2.61% |
47 more rows. Subscribe for $29/month to see every row, download the data and use the API.